Impact of Pharmacist Counselling on Clozapine Knowledge

Clozapine is the only antipsychotic with evidence for efficacy in treatment of resistant schizophrenia but it carries a high sideeffect burden. Patient information is provided but may be poorly retained. This study aims to examine the impact of pharmacistcounselling upon patient knowledge of clozapine. Outpatients, aged 18 years and over, attending St. Patrick’s University Hospital,Dublin, participated in this study between June and August 2015. The intervention consisted of pharmacist counselling on twooccasions one month apart. Knowledge was assessed using a 28-point checklist devised from the currently available clozapinepatient information sources, at baseline and after each counselling session. Ethics approval was obtained. Twenty-five participants(40% female; mean age 45.1 years, SD 9.82; 64% unemployed, 28% smokers) showed an improvement in knowledge scores ofclozapine from baseline to postcounselling on each occasion with an overall improvement in knowledge score, from baseline topostcounselling at one month, of 39.43%;𝑝 < 0.001. This study adds to the evidence that interventions involving pharmacistcounselling can improve patient knowledge, whilst the specific knowledge gained relating to recognition of side effects may helppatients towards more empowerment regarding their treatment